A new weight loss drug developed by Amgen may provide better results with fewer injections than current treatments such as ...

Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...